{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ITGR",
  "name": "Integer Holdings Corporation",
  "url": "https://orbyd.app/dossiers/ITGR/",
  "json_url": "https://orbyd.app/dossiers/ITGR.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "The equity is now a deal instrument: KKR's $127 all-cash agreement, signed 2026-08-03, leaves $1.73 of headline consideration above the 2026-08-07 close of $125.27, while a break returns it toward the $96–$110 pre-leak analyst zone. Closing is guided to year-end 2026; outside date 2027-05-02.",
  "invalidation_trigger": "A daily close below $118 — more than a 7% discount to the $127 cash consideration and well outside the band a fully committed, no-financing-condition deal trades in — marks the market repricing completion odds; an HSR second request or a proxy guiding close into H1 2027 would confirm.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Integer withdrew its FY2026 financial outlook on 2026-08-03 for the pendency of the KKR transaction — no company forecast exists while the merger is outstanding.",
    "Upside is contractually capped at $127 cash absent a superior proposal; the agreement carries a $154M company termination fee and a $307M parent reverse termination fee.",
    "Unvested RSU/PSU awards are 50% cashed out at closing and 50% remain subject to existing service vesting under the merger agreement (2026-08-03).",
    "NYSE-listed; the shares delist on closing, guided by the company to year-end 2026 with a merger-agreement outside date of 2027-05-02.",
    "Delaware Court of Chancery is the exclusive forum for certain merger-related actions under the deal documents filed 2026-08-03."
  ],
  "body_markdown": "## Current Thesis\nSince 2026-08-03 this has been a signed-deal instrument. KKR's affiliate agreed to acquire Integer for **$127.00 per share in cash**, an enterprise value of approximately $5.7B, with the board unanimously recommending the transaction. The last completed daily close was **$125.27 (2026-08-07)**; the gap to the stated consideration is $1.73, roughly 1.4% of that close. The narrative an investor would be buying is no longer medical-device contract manufacturing — it is completion odds on a fully committed, no-financing-condition take-private guided to close by year-end 2026 against an outside date of **2027-05-02**. Everything above $127 requires a competing bid that does not currently exist.\n\n## Bull Case\n- **Definitive agreement, not a proposal (2026-08-03):** all-cash $127, EV ~$5.7B, equity from KKR-managed funds plus committed debt. No financing contingency. Lead arrangers named in the announcement: Citi, KKR Capital Markets, Barclays, UBS, Jefferies.\n- **Fee asymmetry favors the seller:** parent reverse termination fee **$307M** versus a **$154M** company fee, per the merger-agreement terms filed with the 2026-08-03 8-K. The $154M company fee sits against a ~$5.7B EV, which is not a prohibitive toll on a topping bid.\n- **The Q2 print landed the same day and beat:** sales **$464.110M** vs **$450.505M** consensus; adjusted EPS **$1.60** vs **$1.42** consensus (2026-08-03). A quarter that clears expectations into signing weakens any later material-adverse-effect argument.\n- **Financial-sponsor buyer:** KKR carries no medical-device manufacturing overlap with Integer, so the horizontal-overlap path to an antitrust problem is narrower than in a strategic combination. This is an inference from the buyer's identity, not a disclosed regulatory position.\n- **Runway:** the 2027-05-02 outside date leaves roughly nine months against a year-end 2026 closing guide — slack for a second request or a slow proxy without the agreement lapsing.\n- **Premium is already banked:** $127 was disclosed as a 51.8% premium to the 2026-04-29 close and 28.8% to the 30-day VWAP through 2026-07-31.\n\n## Bear Case\n- **Upside is contractually capped.** At $125.27 (2026-08-07) the remaining headline consideration is $1.73. There is no fundamental path above $127 while this agreement stands.\n- **Sell-side has already collapsed onto the deal price.** KeyBanc to Sector Weight (2026-08-03); Oppenheimer to Perform (2026-08-04); Truist to Hold with PT **$127**; Wells Fargo Equal-Weight with PT **$127** (both 2026-08-04). Four houses neutralized inside 48 hours and two targets set precisely at the consideration.\n- **The un-deal anchors are far below.** Pre-leak marks: Citi Neutral **PT $96** (2026-07-08), Truist Buy **PT $110** (2026-07-16). A break returns the equity toward that zone, roughly 12–24% below the 2026-08-07 close.\n- **The standalone business is shrinking.** Q2 2026 sales fell 2.6% YoY, organic sales -1.5%. Integer **withdrew its previously issued FY2026 outlook** on 2026-08-03 because of the pending transaction, so no company forecast exists to underwrite a break price.\n- **Funding still has to clear.** No financing condition is a contractual protection, not a market one; a ~$5.7B EV LBO syndication remains exposed to credit conditions between signing and funding.\n- **RSI(14) 95.6 and a +42.2% three-month return through 2026-08-07 are step-function artifacts** of the 2026-07-31 leak and the 2026-08-03 signing. Those readings will pull momentum and breakout screens toward a security whose contractual upside is $1.73.\n\n## Setup & Price Structure\n- **2026-07-31:** WSJ reported KKR near a deal at roughly $127. Shares were halted on an upside circuit breaker with the stock up 11.05%, then resumed the same session.\n- **2026-08-03:** definitive agreement plus Q2 results. The gap between the pre-leak trading range and $127 closed in two sessions.\n- **2026-08-07:** close **$125.27**; 52-week high **$126.07**, i.e. 0.6% below the high. The 52-week high itself sits $0.93 under the cash consideration.\n- **Structure now:** post-announcement pinning. Price action is a narrow band beneath $127, and the distribution is bimodal — closing at $127 or breaking toward the pre-leak analyst zone. Conventional trend geometry (rising moving averages, breakout shelves) carries no information about a price fixed by contract.\n- **Life-cycle: SATURATED.** Dated by the 2026-08-03/2026-08-04 downgrade cluster, by two price targets set at exactly the deal price, and by a share price parked within 0.6% of a 52-week high that is capped above by the merger agreement. Mainstream coverage is complete and there is no incremental fundamental bid.\n- **What would flip it back to ACCELERATING:** a superior proposal or an amended price above $127. Absent that, the only remaining variable is time-to-close.\n- **Positioning observables:** four analyst rating changes to neutral within 48 hours of announcement; two targets pinned at $127; RSI(14) 95.6; no insider Form 4 activity in the filing record reviewed as of 2026-08-08. Under the merger agreement, unvested RSU/PSU awards are 50% cashed out at closing with 50% remaining subject to existing service vesting — management's remaining economics are tied to the deal completing rather than to the tape.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-09-02 (est.)** — preliminary merger proxy (PREM14A). Not filed as of 2026-08-08. It sets the special-meeting date and discloses the background of the merger, the financial analysis, and the full deal-protection package.\n- **~2026-09-15 (est.)** — expiry of the HSR initial 30-day waiting period. The filing date has not been disclosed, so this window is an estimate; a second request rather than expiry is the observable that matters.\n- **2026-12-31** — the company's stated closing target (\"by the end of the year,\" 2026-08-03 announcement). No confirmed hard-dated catalyst falls inside the next 30 days.\n- **2027-05-02** — outside date under the merger agreement. Beyond the 30-day window but the binding constraint on the timeline.\n\n## What Would Change Our Mind\nThe thesis breaks the moment the spread stops behaving like a funded deal's. A fully committed, no-financing-condition agreement with a $307M reverse fee normally trades within a point or two of consideration; persistent widening means the market is re-underwriting completion odds rather than discounting time. Concretely: **a daily close below $118** — a discount of more than 7% to the $127 cash consideration — is the gradeable break.\n\nSecondary conditions that would independently change the read:\n- An 8-K disclosing an HSR **second request**, or a proxy that guides closing into H1 2027 rather than year-end 2026 — both stretch the holding period without improving the payoff.\n- The 2026-12-31 closing guide passing without a completed transaction and without a stated new target date.\n- On the other side: any disclosed superior proposal above $127 would reopen upside and move the life-cycle label off SATURATED.\n- A DEFA14A disclosing that a proxy advisor recommends against the merger, or litigation that adjourns the special meeting.\n\n## Correlation Notes\n- Since the 2026-08-03 signing, the driver set is deal completion rather than orthopedic/cardio end-market demand. Correlation to medtech peers and to broad healthcare beta should decay toward zero while the agreement stands; this is an inference from deal mechanics, and the observable that confirms it is price remaining pinned in a narrow band under $127 through peer-group moves.\n- The relevant correlated cohort is other pending sponsor take-privates and the leveraged loan / high-yield market, because funding for a ~$5.7B EV LBO clears through it. A financing shock at one large sponsor deal historically widens spreads across the cohort at the same time.\n- The Q2 2026 fundamental data (sales -2.6% YoY, organic -1.5%, 2026-08-03) matters only conditionally: it is irrelevant to a completing deal and is the valuation anchor if the deal breaks, alongside the pre-leak targets of $96 (Citi, 2026-07-08) and $110 (Truist, 2026-07-16).\n- Withdrawn FY2026 guidance removes the usual quarterly re-rating mechanism, so the security will not respond to sector estimate revisions the way it did before 2026-07-31.",
  "first_seen": "2026-08-04",
  "last_analyzed": "2026-08-08T09:17:10+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}